Bevirimat

Drug Profile

Bevirimat

Alternative Names: Bevirimat dimeglumine; MPC-4326; PA 103001-04; PA-457

Latest Information Update: 26 Nov 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Panacos Pharmaceuticals Inc; University of North Carolina
  • Developer Myrexis
  • Class Antivirals; Small molecules; Succinates; Triterpenes
  • Mechanism of Action HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Suspended HIV-1 infections

Most Recent Events

  • 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
  • 08 Jun 2010 Myrexis suspends its HIV maturation program for strategic business reasons
  • 08 Jun 2010 Suspended - Phase-II for HIV-1 infections in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top